Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Stem cells have been the focus of intense research opening up new possibilities for the treatment of various diseases. Mesenchymal stromal cells (MSCs) are multipotent cells with relevant immunomodulatory properties and are thus considered as a promising new strategy for immune disease management. To enhance their efficiency, several issues related to both MSC biology and functions are needed to be identified and, most importantly, well clarified. The sources from which MSCs are isolated are diverse and might affect their properties. Both clinicians and scientists need to handle a phenotypic-characterized population of MSCs, particularly regarding their immunological profile. Moreover, it is now recognized that the tissue-reparative effects of MSCs are based on their immunomodulatory functions that are activated following a priming/licensing step. Thus, finding the best ways to pre-conditionate MSCs before their injection will strengthen their activity potential. Finally, soluble elements derived from MSC-secretome, including extracellular vesicles (EVs), have been proposed as a cell-free alternative tool for therapeutic medicine. Collectively, these features have to be considered and developed to ensure the efficiency and safety of MSC-based therapy. By participating to this Special Issue “Mesenchymal Stem/Stromal Cells in Immunity and Disease”, your valuable contribution will certainly enrich the content and discussion related to the thematic of MSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., Redl, H., Rubin, J. P., Yoshimura, K., & Gimble, J. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.006 · Cited by 1,890 · cited 1×
“Moreover, in order to achieve uniform characterization of MSCs and facilitate the comparison of data among investigators, the ISCT as well as the International Federation for Adipose Therapeutics and Science (IFATS) have established a minimal set of standard criteria to define human MSCs according to their tissue orig…”
BackgroundPlasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
Wang, Y., Chen, X., Cao, W., & Shi, Y. (2014) · Nature Immunology · doi:10.1038/ni.3002 · Cited by 1,452
Mechanisms involved in the therapeutic properties of mesenchymal stem cells
da Silva Meirelles, L., Fontes, A. M., Covas, D. T., & Caplan, A. I. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.10.002 · Cited by 1,436 · cited 1×
“Due to their simple and easier isolation procedure as well as their great expansion potential, MSCs are ideal candidates for different cellular therapies [4].”
Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363 · cited 1×
“Secretome derivatives, such as conditioned media or exosomes, may present considerable advantages over cells for manufacturing, storage, handling, product shelf life, and their potential as a ready-to-go biologic product [29].”
Background
Cited by
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01855-9 · Cited by 343
The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity
Zhou, Y., Yamamoto, Y., Xiao, Z., & Ochiya, T. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071025 · Cited by 303
Mesenchymal Stem Cell Therapy and Alzheimer’s Disease: Current Status and Future Perspectives
Kim, J., Lee, Y., Lee, S., Kim, K., Song, M., & Lee, J. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200219 · Cited by 73
Zhao, Y., Haney, M. J., Fallon, J. K., Rodriguez, M., Swain, C. J., Arzt, C. J., Smith, P. C., Loop, M. S., Harrison, E. B., El-Hage, N., et al. (2022) · Cells · doi:10.3390/cells11121933 · Cited by 39
“Most of them, especially using Mesenchymal Stem Cells (MSCs) derived EVs showed no safety concerns, high feasibility, and significant enhancement of antitumor immune response [30-34].”
BackgroundBiocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases
Neupane, Y. R., Mahtab, A., Siddiqui, L., Singh, A., Gautam, N., Rabbani, S. A., Goel, H., & Talegaonkar, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200523174108 · Cited by 21
Metadata
- Authors
- Najar, M., Bouhtit, F., Melki, R., Afif, H., Hamal, A., Fahmi, H., Merimi, M., & Lagneaux, L.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2019-05-08
- Volume
- 8
- Issue
- 5
- Pages
- 626
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2944107544
- Cited by
- 91
- References
- 4
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges. https://app.cochat.ai/papers/10.3390/jcm8050626
- The paper
- Najar, M., Bouhtit, F., Melki, R., Afif, H., Hamal, A., Fahmi, H., Merimi, M., & Lagneaux, L. (2019). Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges. Journal of Clinical Medicine. https://doi.org/10.3390/jcm8050626
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.